Evidence map›Paper›PMID 26656104›Full record

ArticlePLoS genetics2015

Tyro3 Modulates Mertk-Associated Retinal Degeneration.

Douglas Vollrath, Douglas Yasumura, Gillie Benchorin, Michael T Matthes, Wei Feng, Natalie M Nguyen, Cecilia D Sedano, Melissa A Calton, Matthew M LaVail

Open access · goldAbstract read
In one paragraph

Article in PLoS genetics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. MERTK Inhibition as a Targeted Novel Cancer Therapy.International journal of molecular sciences · 2024
    Review
  6. In the Eyes of the Beholder-NewInternational journal of molecular sciences · 2024
    Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Douglas VollrathDepartment of Genetics, Stanford University School of Medicine, Stanford, California, United States of America.
Douglas YasumuraBeckman Vision Center, University of California San Francisco, San Francisco, California, United States of America.
Gillie BenchorinDepartment of Genetics, Stanford University School of Medicine, Stanford, California, United States of America.
Michael T MatthesBeckman Vision Center, University of California San Francisco, San Francisco, California, United States of America.
Wei FengDepartment of Genetics, Stanford University School of Medicine, Stanford, California, United States of America.
Natalie M NguyenDepartment of Genetics, Stanford University School of Medicine, Stanford, California, United States of America.
Cecilia D SedanoDepartment of Genetics, Stanford University School of Medicine, Stanford, California, United States of America.
Melissa A CaltonDepartment of Genetics, Stanford University School of Medicine, Stanford, California, United States of America.
Matthew M LaVailBeckman Vision Center, University of California San Francisco, San Francisco, California, United States of America.
Stanford University · USUniversity of California, San Francisco · US

Funding

Rapid-Prototyping and Design CoreP30EY002162 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI OU, YVONNE · 1985 to 2024
$16.8M
CELLULAR MECHANISMS OF INHERITED RETINAL DEGENERATIONR01EY001919 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LAVAIL, MATTHEW M · 1985 to 2014
$8.3M
RODENT MODELS OF RETINAL DEGENERATIONR01EY006842 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LAVAIL, MATTHEW M · 1992 to 2014
$3.6M
Vision Research Training ProgramT32EY020485 · NEI · STANFORD UNIVERSITY · PI BARRES, BEN A, LIAO, YAPING JOYCE · 2010 to 2014
$795k
NEUROPHYSIOLOGY OF INTERMEDIATE LEVEL VISIONF32EY006842 · NEI · ROCKEFELLER UNIVERSITY · PI BAKIN, JONATHAN S · 1997 to 1999
–
CELLULAR MECHANISMS OF INHERITED RETINAL DEGENERATIONR37EY001919 · NEI · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · PI LAVAIL, MATTHEW M · 1989 to 1998
–
BREEDING COLONY WITH INHERITED RETINAL DYSTROPHYU01EY006842 · NEI · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · PI LAVAIL, MATTHEW M · 1986 to 1992
–
NEI NIH HHS EY001919NEI NIH HHS EY002162NEI NIH HHS EY006842NEI NIH HHS EY20485NEI NIH HHS F32 EY006842NEI NIH HHS P30 EY002162NEI NIH HHS R01 EY001919NEI NIH HHS R01 EY006842NEI NIH HHS T32 EY020485
6 · The paper itself

Abstract

Inherited photoreceptor degenerations (IPDs) are the most genetically heterogeneous of Mendelian diseases. Many IPDs exhibit substantial phenotypic variability, but the basis is usually unknown. Mutations in MERTK cause recessive IPD phenotypes associated with the RP38 locus. We have identified a murine genetic modifier of Mertk-associated photoreceptor degeneration, the C57BL/6 (B6) allele of which acts as a suppressor. Photoreceptors degenerate rapidly in Mertk-deficient animals homozygous for the 129P2/Ola (129) modifier allele, whereas animals heterozygous for B6 and 129 modifier alleles exhibit an unusual intermixing of degenerating and preserved retinal regions, with females more severely affected than males. Mertk-deficient mice homozygous for the B6 modifier allele display degeneration only in the far periphery, even at 8 months of age, and have improved retinal function compared to animals homozygous for the 129 allele. We genetically mapped the modifier to an approximately 2-megabase critical interval that includes Tyro3, a paralog of Mertk. Tyro3 expression in the outer retina varies with modifier genotype in a manner characteristic of a cis-acting expression quantitative trait locus (eQTL), with the B6 allele conferring an approximately three-fold higher expression level. Loss of Tyro3 function accelerates the pace of photoreceptor degeneration in Mertk knockout mice, and TYRO3 protein is more abundant in the retinal pigment epithelium (RPE) adjacent to preserved central retinal regions of Mertk knockout mice homozygous for the B6 modifier allele. Endogenous human TYRO3 protein co-localizes with nascent photoreceptor outer segment (POS) phagosomes in a primary RPE cell culture assay, and expression of murine Tyro3 in cultured cells stimulates phagocytic ingestion of POS. Our findings demonstrate that Tyro3 gene dosage modulates Mertk-associated retinal degeneration, provide strong evidence for a direct role for TYRO3 in RPE phagocytosis, and suggest that an eQTL can modify a recessive IPD.

Indexed as

Animalsc-Mer Tyrosine KinaseDisease Models, AnimalHumansMiceMice, KnockoutPhagocytosisPhotoreceptor CellsProto-Oncogene ProteinsReceptor Protein-Tyrosine KinasesRetinaRetinal DegenerationRetinal Pigment Epitheliumc-Mer Tyrosine KinaseMERTK protein, humanMertk protein, mouseProto-Oncogene ProteinsReceptor Protein-Tyrosine KinasesTyro3 protein, mouse

Identifiers

PMID26656104
PMCPMC4687644
OpenAlexW2189808142

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.